Abbott Laboratories Intrinsic Value Calculator – Abbott Laboratories Achieves $192bn Market Cap with Long View Investment Strategy
February 1, 2023
Trending News 🌥️
Abbott Laboratories Intrinsic Value Calculator – The company’s success can be attributed to its focus on long-term investment strategies and its four major divisions: Established Pharmaceutical Products, Nutritional Products, Diagnostic Products and Medical Devices. Over the past eight years, Abbott ($NYSE:ABT) has seen tremendous growth in revenue, rising from $19bn to $30bn in 2020. This can be mainly attributed to the successful spinoff of its Pharmaceuticals and Drug Development division into AbbVie, now valued at over $250bn. Abbott is also known for its commitment to innovation and has invested heavily in research and development, leading to the introduction of several significant new products in recent years. Abbott’s long-term investment strategy has enabled the company to build strong relationships with customers and suppliers, which has in turn allowed them to grow their business over the years. The company is well-positioned for future growth with a strong portfolio of products and services, as well as a broad global reach.
In addition, Abbott has a strong financial footing, with a robust balance sheet and plenty of cash on hand for strategic investments. With its focus on long-term growth and strong financials, Abbott is well positioned to continue its success in the future.
Share Price
The success of Abbott Laboratories can be attributed to their long-term investment strategy. They have consistently invested in research and development projects, as well as in product development and marketing initiatives, which have enabled them to remain ahead of the competition.
Additionally, Abbott has built a strong global presence by expanding into emerging markets and developing strategic collaborations with other healthcare companies. These acquisitions have enabled Abbott to expand their product portfolio and gain access to innovative technologies. In addition to its strong investment strategy, Abbott has also taken a proactive approach to managing its finances. They have implemented a variety of cost-saving initiatives, such as reducing overhead expenses and increasing efficiency in their operations. This has allowed them to generate higher profits and maximize their shareholders’ return on investment. The impressive market capitalization of Abbott Laboratories is a testament to their long-term investment strategy and sound financial management. With this achievement, they have demonstrated that it is possible to succeed in the healthcare industry by taking a long-term view and making wise investments. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Abbott Laboratories. More…
| Total Revenues | Net Income | Net Margin |
| 43.65k | 6.93k | 15.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Abbott Laboratories. More…
| Operations | Investing | Financing |
| 10.32k | -2.01k | -5.49k |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Abbott Laboratories. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 72.8k | 36.92k | 20.46 |
Key Ratios Snapshot
Some of the financial key ratios for Abbott Laboratories are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 11.0% | 22.7% | 19.9% |
| FCF Margin | ROE | ROA |
| 19.6% | 15.2% | 7.5% |
VI Analysis – Abbott Laboratories Intrinsic Value Calculator
ABBOTT LABORATORIES is a great stock for long-term investors, and our VI app makes it easy to analyze its fundamentals. Our proprietary VI Line indicator shows a fair value of $127.4 for ABBOTT LABORATORIES share, which is currently trading at $109.8 per share, a 13.8% discount from the fair price. This indicates that ABBOTT LABORATORIES is currently undervalued, making it an attractive buy for long-term investors. The company has a wide range of products, from pharmaceuticals and medical devices to nutritional products and diagnostics. Their business model is highly diversified and their balance sheet is strong, with a steady cash flow and profitability. Furthermore, the company has a well-established brand and a long history of innovation, which have allowed it to remain competitive in the market. With its current valuation, ABBOTT LABORATORIES is an attractive investment opportunity for long-term investors. The company’s fundamentals are strong and its market position is secure, making it a reliable stock to add to one’s portfolio. Moreover, its current undervaluation provides investors with an opportunity to buy shares at a discount. Therefore, investors should consider ABBOTT LABORATORIES as a potential pick for their portfolios. More…
VI Peers
Abbott Laboratories is a large, publicly traded company that manufactures and sells medical products, including diagnostics, devices, and branded generic pharmaceuticals. The company has a diversified product portfolio and a strong presence in multiple global markets. However, Abbott Laboratories faces stiff competition from other large medical companies, such as OraSure Technologies Inc, Quidel Corp, and Lucira Health Inc.
– OraSure Technologies Inc ($NASDAQ:OSUR)
OraSure Technologies Inc is a leader in developing, manufacturing, and marketing oral fluid diagnostic products. The company’s products are used for the detection of antibodies to HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide. The company has a market cap of 283.94M as of 2022, a Return on Equity of -8.39%.
OraSure Technologies is dedicated to improving global health by developing and delivering innovative point-of-care diagnostic solutions to meet the needs of underserved populations. The company’s products are used for the detection of infectious diseases, such as HIV and HCV, as well as for the detection of drugs of abuse. OraSure’s products are sold in over 60 countries worldwide.
– Quidel Corp ($NASDAQ:QDEL)
Quidel Corporation is a molecular diagnostics company, providing diagnostic solutions that empower patients and physicians to make better healthcare decisions. The company has a market cap of $5.18 billion and a return on equity of 22.75%. Quidel’s products are used in a variety of settings, including hospitals, physician offices, and retail pharmacies. Quidel’s products are used to diagnose a wide range of conditions, including influenza, respiratory syncytial virus, and tuberculosis. Quidel also offers a variety of point-of-care tests, including tests for pregnancy, ovulation, and infectious diseases.
– Lucira Health Inc ($NASDAQ:LHDX)
Lucira Health Inc is a medical technology company that develops and commercializes molecular diagnostics products. The company’s products are designed to enable earlier and more accurate detection of infectious diseases. Lucira Health’s products include the Lucira COVID-19 All-In-One Test Kit, which is the first FDA-cleared molecular test for the self-collection and detection of COVID-19. The company has a market cap of $46.12 million and a return on equity of -13.64%.
Summary
The company has achieved this success by focusing on steady, gradual growth and diversification of investments, rather than taking high-risk, short-term strategies. Abbott has invested in a wide range of industries, from healthcare to financial services, and has built a solid portfolio of stocks and bonds. They have also been active in mergers and acquisitions, allowing them to capitalize on new markets and businesses.
Abbott’s approach has enabled them to weather any economic downturns and remain profitable. Overall, their investment strategy has proven successful in driving growth and creating value for shareholders.
